Zentalis Historical Income Statement

ZNTL Stock

USD 3.66 0.05 1.39%

Historical analysis of Zentalis Pharmaceuticals income statement accounts such as Net Interest Income of 469.1 K, Interest Income of 469.1 K, Depreciation And Amortization of 1.5 M or Interest Expense of 2.8 M can show how well Zentalis Pharmaceuticals Llc performed in making a profits. Evaluating Zentalis Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Zentalis Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Zentalis Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Zentalis Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About Zentalis Income Statement Analysis

Zentalis Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Zentalis Pharmaceuticals shareholders. The income statement also shows Zentalis investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Zentalis Pharmaceuticals Income Statement Chart

At this time, Zentalis Pharmaceuticals' Depreciation And Amortization is quite stable compared to the past year. Reconciled Depreciation is expected to rise to about 1.5 M this year, although the value of Tax Provision is projected to rise to (784.7 K).

Depreciation And Amortization Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Zentalis Pharmaceuticals. It is also known as Zentalis Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Zentalis Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Zentalis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

	2010	2019	2023	2024 (projected)
Interest Income	355K	498K	572.7K	469.2K
Net Interest Income	355K	498K	572.7K	469.2K

Interest Income Net Interest Income

Zentalis Pharmaceuticals income statement Correlations

	Tax Provision	Net Interest Income	Interest Income	Depreciation And Amortization	Selling General Administrative	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Minority Interest	Cost Of Revenue	Non Operating Income Net Other	Selling And Marketing Expenses
Tax Provision		-0.54	-0.54	-0.9	-0.69	0.88	-0.72	0.78	0.83	0.82	-0.73	0.82	-0.72	-0.9	0.82	0.33	0.83	0.99	0.78	-0.84	0.87	0.77
Net Interest Income	-0.54		1.0	0.73	0.89	-0.77	0.88	-0.86	-0.84	-0.85	0.88	-0.85	0.88	0.73	-0.85	-0.06	-0.85	-0.5	-0.27	0.74	-0.64	-0.43
Interest Income	-0.54	1.0		0.73	0.89	-0.77	0.88	-0.86	-0.84	-0.85	0.88	-0.85	0.88	0.73	-0.85	-0.06	-0.85	-0.5	-0.27	0.74	-0.64	-0.43
Depreciation And Amortization	-0.9	0.73	0.73		0.89	-1.0	0.88	-0.93	-0.96	-0.96	0.87	-0.96	0.88	1.0	-0.96	-0.32	-0.96	-0.88	-0.56	0.95	-0.97	-0.73
Selling General Administrative	-0.69	0.89	0.89	0.89		-0.91	0.99	-0.97	-0.95	-0.95	0.98	-0.95	0.99	0.89	-0.95	-0.06	-0.95	-0.67	-0.4	0.92	-0.81	-0.49
Gross Profit	0.88	-0.77	-0.77	-1.0	-0.91		-0.91	0.94	0.97	0.97	-0.9	0.97	-0.91	-1.0	0.97	0.29	0.97	0.87	0.55	-0.97	0.97	0.69
Other Operating Expenses	-0.72	0.88	0.88	0.88	0.99	-0.91		-0.98	-0.94	-0.95	1.0	-0.95	1.0	0.88	-0.95	0.03	-0.94	-0.72	-0.51	0.91	-0.78	-0.48
Operating Income	0.78	-0.86	-0.86	-0.93	-0.97	0.94	-0.98		0.98	0.98	-0.98	0.98	-0.98	-0.93	0.98	0.05	0.98	0.76	0.53	-0.89	0.83	0.62
Net Income From Continuing Ops	0.83	-0.84	-0.84	-0.96	-0.95	0.97	-0.94	0.98		1.0	-0.94	1.0	-0.94	-0.96	1.0	0.24	1.0	0.79	0.47	-0.91	0.9	0.73
Ebit	0.82	-0.85	-0.85	-0.96	-0.95	0.97	-0.95	0.98	1.0		-0.94	1.0	-0.95	-0.96	1.0	0.23	1.0	0.78	0.47	-0.91	0.9	0.72
Research Development	-0.73	0.88	0.88	0.87	0.98	-0.9	1.0	-0.98	-0.94	-0.94		-0.94	1.0	0.87	-0.94	0.07	-0.93	-0.73	-0.55	0.9	-0.76	-0.47
Ebitda	0.82	-0.85	-0.85	-0.96	-0.95	0.97	-0.95	0.98	1.0	1.0	-0.94		-0.95	-0.96	1.0	0.23	1.0	0.78	0.47	-0.91	0.89	0.72
Total Operating Expenses	-0.72	0.88	0.88	0.88	0.99	-0.91	1.0	-0.98	-0.94	-0.95	1.0	-0.95		0.88	-0.95	0.04	-0.94	-0.72	-0.51	0.91	-0.78	-0.48
Reconciled Depreciation	-0.9	0.73	0.73	1.0	0.89	-1.0	0.88	-0.93	-0.96	-0.96	0.87	-0.96	0.88		-0.96	-0.32	-0.96	-0.88	-0.55	0.95	-0.97	-0.73
Income Before Tax	0.82	-0.85	-0.85	-0.96	-0.95	0.97	-0.95	0.98	1.0	1.0	-0.94	1.0	-0.95	-0.96		0.23	1.0	0.78	0.47	-0.91	0.89	0.72
Total Other Income Expense Net	0.33	-0.06	-0.06	-0.32	-0.06	0.29	0.03	0.05	0.24	0.23	0.07	0.23	0.04	-0.32	0.23		0.25	0.22	-0.24	-0.22	0.49	0.61
Net Income	0.83	-0.85	-0.85	-0.96	-0.95	0.97	-0.94	0.98	1.0	1.0	-0.93	1.0	-0.94	-0.96	1.0	0.25		0.79	0.47	-0.91	0.9	0.74
Income Tax Expense	0.99	-0.5	-0.5	-0.88	-0.67	0.87	-0.72	0.76	0.79	0.78	-0.73	0.78	-0.72	-0.88	0.78	0.22	0.79		0.85	-0.84	0.85	0.68
Minority Interest	0.78	-0.27	-0.27	-0.56	-0.4	0.55	-0.51	0.53	0.47	0.47	-0.55	0.47	-0.51	-0.55	0.47	-0.24	0.47	0.85		-0.56	0.46	0.33
Cost Of Revenue	-0.84	0.74	0.74	0.95	0.92	-0.97	0.91	-0.89	-0.91	-0.91	0.9	-0.91	0.91	0.95	-0.91	-0.22	-0.91	-0.84	-0.56		-0.93	-0.52
Non Operating Income Net Other	0.87	-0.64	-0.64	-0.97	-0.81	0.97	-0.78	0.83	0.9	0.9	-0.76	0.89	-0.78	-0.97	0.89	0.49	0.9	0.85	0.46	-0.93		0.73
Selling And Marketing Expenses	0.77	-0.43	-0.43	-0.73	-0.49	0.69	-0.48	0.62	0.73	0.72	-0.47	0.72	-0.48	-0.73	0.72	0.61	0.74	0.68	0.33	-0.52	0.73

Click cells to compare fundamentals

Zentalis Pharmaceuticals Account Relationship Matchups

Zentalis Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Tax Provision	15K	444K	(297K)	(469K)	(826K)	(784.7K)
Depreciation And Amortization	111K	160K	544K	1.4M	1.4M	1.5M
Interest Expense	1.2M	2.2M	110.0M	2.6M	3.0M	2.8M
Selling General Administrative	8.5M	33.9M	40.9M	54.6M	59.4M	37.1M
Gross Profit	(111K)	(160K)	(544K)	(1.4M)	(1.4M)	(1.3M)
Other Operating Expenses	46.8M	118.8M	216.5M	227.3M	253.9M	162.7M
Operating Income	(46.8M)	(118.8M)	(216.5M)	(227.3M)	(249.0M)	(236.5M)
Net Income From Continuing Ops	(46.4M)	(118.5M)	(164.3M)	(220.8M)	(286.4M)	(272.0M)
Ebit	(46.8M)	(118.1M)	(164.6M)	(221.3M)	(276.9M)	(263.0M)
Research Development	38.4M	84.9M	175.6M	172.7M	189.6M	124.7M
Ebitda	(46.7M)	(117.9M)	(164.0M)	(219.9M)	(275.5M)	(261.7M)
Total Operating Expenses	46.8M	118.8M	216.5M	227.3M	252.6M	162.4M
Reconciled Depreciation	111K	160K	544K	1.4M	1.4M	1.5M
Income Before Tax	(46.4M)	(118.1M)	(164.6M)	(221.3M)	(276.9M)	(263.0M)
Total Other Income Expense Net	482K	683K	52.0M	6.0M	(27.9M)	(26.5M)
Net Income Applicable To Common Shares	(45.7M)	(117.8M)	(158.7M)	(236.8M)	(213.1M)	(202.5M)
Net Income	(46.4M)	(118.5M)	(164.3M)	(220.8M)	(292.2M)	(277.6M)
Income Tax Expense	15K	444K	(297K)	(469K)	(601K)	(571.0K)
Minority Interest	6.8M	24.8M	(7.4M)	(307K)	105K	99.8K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:

How To Invest In Zentalis

Details

Is Zentalis Stock a good investment?

Details

What is Zentalis Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.50)

Revenue Per Share

0.572

Return On Assets

(0.25)

Return On Equity

(0.43)

The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Zentalis Historical Income Statement

About Zentalis Income Statement Analysis

Zentalis Pharmaceuticals Income Statement Chart

Depreciation And Amortization

Other Operating Expenses

Total Operating Expenses

Zentalis Pharmaceuticals income statement Correlations

Zentalis Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Zentalis Pharmaceuticals income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Interest Income	+ 1.0	Net Interest Income
Reconciled Depreciation	+ 1.0	Depreciation And Amortization
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Net Income From Continuing Ops
Ebitda	+ 1.0	Net Income From Continuing Ops

Reconciled Depreciation	- 1.0	Gross Profit
Gross Profit	- 1.0	Depreciation And Amortization
Total Operating Expenses	- 0.98	Operating Income
Research Development	- 0.98	Operating Income
Operating Income	- 0.98	Other Operating Expenses
Non Operating Income Net Other	- 0.97	Reconciled Depreciation